Pharma Business - May 2, 2016
Kancera acquires Fractalkine project
Swedish Kancera is to acquire Fractalkine project from Acturum Life Science and the payment for is to be carried in three steps with total of 6 million shares. Due to positive efficacy data in disease models of cancer and pain, Kancera’s Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project. Kancera […]
Drug Development Pharma - February 27, 2013
Acturum takes over AstraZeneca facilities
AstraZeneca’s facility Snäckviken in Södertälje has been acquired by Acturum and will from now on be called BiovationPark Telge. The facility will host SP process development, Scania, Campus Telge and around 20 small research companies. Besides laboratories and offices, Acturum will install 5000 laboratory instruments at the facility. Astra will also hand over 15 drug […]